Transient receptor potential channel

Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis

Retrieved on: 
Tuesday, November 22, 2022
Issuer, Allergen, TRPV1, Network congestion, European Forum of Medical Associations, Euronext, University, Rhinorrhea, Pain, Allergic rhinitis, Overalls, Patient, Sensation, Sleep, Sneeze, Research, Thermoregulation, Webcast, Education, Rhinitis, Information, Faculty of Theology, Old University of Leuven, CET, Nociception, Nasal mucosa, Collection, Quality of life, Transient receptor potential channel, Frustration, Irritability, Atrial fibrillation, Microsoft, Safety, Pharmaceutical industry, Vaccine, Allergy

Idiopathic rhinitis is a medical disorder characterized by a collection of nasal symptoms that resemble nasal allergies and hay fever (allergic rhinitis) but are not caused by a known cause like allergens or infectious triggers.

Key Points: 
  • Idiopathic rhinitis is a medical disorder characterized by a collection of nasal symptoms that resemble nasal allergies and hay fever (allergic rhinitis) but are not caused by a known cause like allergens or infectious triggers.
  • Idiopathic rhinitis features an overexpression of TRPV1 in the nasal mucosa giving rise to nasal obstruction, rhinorrhoea (colloquially: a runny nose), and/or sneezing.
  • Hyloris treatment approach is to activate and depolarize TRPV1 receptors leading to restoration of a normal function of the nasal mucosa.
  • Stijn Van Rompay, Chief Executive Officer of Hyloris,commented: We are pleased to announce another value-added product candidate to add to our portfolio of programs.

Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain

Retrieved on: 
Monday, January 10, 2022
Health, Pain, Alzheimer's disease, U.S. Securities and Exchange Commission, Annual report, Program, Partnership, Migraine, European Investment Fund, Tic disorder, FDA, Technology transfer, Pain management, TRP, Ion, Security (finance), Board, Student, Science, Center, MPO, Private Securities Litigation Reform Act, Company, Doctor of Philosophy, Drug design, Chronic pain, Analgesic, Transient receptor potential channel, Pain disorder, Amyotrophic lateral sclerosis, Drug discovery, Patient, Takeda Pharmaceutical Company, Research, Therapy, Transience, NYSE, News, Intellectual property, LICR, Disease, Risk, LRD, Industry, Spinocerebellar ataxia, CGRP, CD3, TRPM3, Pharmaceutical industry, Dentistry, HAVEN, KU Leuven, Development

TRPM3 is a cation channel involved in pain signaling and a novel target for the treatment of pain discovered at KU Leuven's LICR.

Key Points: 
  • TRPM3 is a cation channel involved in pain signaling and a novel target for the treatment of pain discovered at KU Leuven's LICR.
  • There is an urgent unmet need for safe, effective treatments for pain, and TRPM3 antagonism is a promising approach to advance new pain therapies.
  • Under the agreement, Biohaven Therapeutics receives exclusive global rights to develop, manufacture and commercialize KU Leuven's small-molecule TRPM3 antagonists.
  • Biohaven Therapeutics will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders.

TRPV-1 Receptor Antagonist - 2019 Pipeline Insight Report - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 6, 2019
Biotechnology, Pharmaceutical, Health, Ion channels, Branches of biology, TRPV1, Capsaicin, TRPV, Vanilloids, Transient receptor potential channel, Receptor antagonist, Discovery and development of TRPV1 antagonists

The "Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Antagonist development.
  • The report assesses the active Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.
  • Offers detailed therapeutic product profiles of Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine

Neuropathic Pain Markets, 2017-2018 & 2019-2026 - Pfizer Leads Industry Sponsors with the Highest Number of Clinical Trials, Followed by Allergan

Retrieved on: 
Tuesday, June 18, 2019
Branches of biology, Ion channels, Membrane biology, Voltage-gated ion channels, Electrophysiology, Integral membrane proteins, Neuropathic pain, Pfizer, Transient receptor potential channel, TRPV, Voltage-gated calcium channel, EMA401

The marketed drugs in the neuropathic pain space target sodium channels, voltage-gated calcium channels, and transient receptor potential vanilloid receptor 1.

Key Points: 
  • The marketed drugs in the neuropathic pain space target sodium channels, voltage-gated calcium channels, and transient receptor potential vanilloid receptor 1.
  • The majority of industry-sponsored drugs in active clinical development for neuropathic pain are in Phase I.
  • Pfizer has the highest number of completed clinical trials for neuropathic pain, with 230 trials.
  • Pfizer leads industry sponsors with by far the highest number of clinical trials for neuropathic pain, followed by Allergan.